Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mundipharma ab - prednison - tablett med modifierad frisättning - 1 mg - prednison 1 mg aktiv substans; laktosmonohydrat hjälpämne - prednison

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mundipharma ab - prednison - tablett med modifierad frisättning - 5 mg - prednison 5 mg aktiv substans; laktosmonohydrat hjälpämne - prednison

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

meda ab - prednison - tablett - 50 mg - prednison 50 mg aktiv substans; laktosmonohydrat hjälpämne - prednison

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mundipharma ab - prednison - tablett med modifierad frisättning - 2 mg - laktosmonohydrat hjälpämne; prednison 2 mg aktiv substans - prednison

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

nitec pharma gmbh - prednison - tablett med modifierad frisättning - 1 mg - laktosmonohydrat hjälpämne; prednison 1 mg aktiv substans - prednison

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

nitec pharma gmbh - prednison - tablett med modifierad frisättning - 2 mg - laktosmonohydrat hjälpämne; prednison 2 mg aktiv substans - prednison

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

nitec pharma gmbh - prednison - tablett med modifierad frisättning - 5 mg - laktosmonohydrat hjälpämne; prednison 5 mg aktiv substans - prednison

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateronacetat - prostatiska neoplasmer - endokrin terapi - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Europeiska unionen - svenska - EMA (European Medicines Agency)

mylan ireland limited - abirateronacetat - prostatiska neoplasmer - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Europeiska unionen - svenska - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateronacetat - prostatiska neoplasmer - endokrin terapi - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.